id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-0616-0007,FDA,FDA-2016-E-0616,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2017-09-20T04:00:00Z,2017,9,2017-09-20T04:00:00Z,,2017-09-20T18:27:44Z,,0,0,0900006482b64629
FDA-2016-E-0616-0006,FDA,FDA-2016-E-0616,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-12-13T05:00:00Z,2016,12,2016-12-13T05:00:00Z,,2016-12-13T16:29:48Z,,0,0,09000064824015c3
FDA-2016-E-0616-0005,FDA,FDA-2016-E-0616,Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Determinations,2016-12-02T05:00:00Z,2016,12,2016-12-02T05:00:00Z,2017-06-01T03:59:59Z,2016-12-02T17:04:55Z,2016-28917,0,0,09000064823da02e
FDA-2016-E-0616-0004,FDA,FDA-2016-E-0616,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2016-10-13T04:00:00Z,2016,10,2016-10-13T04:00:00Z,,2016-10-13T15:04:20Z,,0,0,09000064822eb5d0
FDA-2016-E-0616-0003,FDA,FDA-2016-E-0616,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-05-09T04:00:00Z,2016,5,2016-05-09T04:00:00Z,,2016-05-09T18:02:43Z,,0,0,0900006481faa61b
FDA-2016-E-0616-0002,FDA,FDA-2016-E-0616,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-02-24T05:00:00Z,2016,2,2016-02-24T05:00:00Z,,2016-02-25T01:15:04Z,,0,0,0900006481e761f8
FDA-2016-E-0616-0001,FDA,FDA-2016-E-0616,"Patent Extension Application from Sterne, Kessler, Goldstein & Fox P.L.L.C (on behalf of E. R. Squibb & Sons, L.L.C. and Ono Pharmaceutical Co., Ltd.)",Other,Application,2016-02-24T05:00:00Z,2016,2,2016-02-24T05:00:00Z,,2016-02-25T01:14:58Z,,0,0,0900006481e76165